Dietilcarbamazina (DEC) en el tratamiento del asma bronquial
Abstract
Se presentan los resultados de un ensayo clínico con dietilcarbamazina (DEC) en el tratamiento de 22 pacientes asmáticos. Los resultados fueron comparados con un grupo testigo de 20 pacientes en un prueba a doble ciegas. Se aplicó el test de X2 para la evaluación de la diferencia entre ambos grupos. El valor obtenido de X2 = 3,07 expresa que la diferencia no fue significativa. Se revisó la literatura disponible sobre el tema y se extrajeron las conclusiones pertinentes.Downloads
Downloads
Published
How to Cite
Issue
Section
License
The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.
You are free to:
- Share - copy and redistribute the material in any medium or format.
- Adapt - remix, transform and build upon the material
- The license cannot revoke these freedoms as long as you follow the terms of the license.
Under the following terms:
- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.
- Non-Commercial Purpose- You may not make use of the material for commercial purposes.
- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.
